China NT Pharma Group Company Limited

SEHK:1011 Stock Report

Market Cap: HK$64.4m

China NT Pharma Group Management

Management criteria checks 3/4

China NT Pharma Group's CEO is David Ng, appointed in Jan 1995, has a tenure of 30.08 years. total yearly compensation is CN¥1.67M, comprised of 99% salary and 1% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth HK$6.10K. The average tenure of the management team and the board of directors is 3.2 years and 7.7 years respectively.

Key information

David Ng

Chief executive officer

CN¥1.7m

Total compensation

CEO salary percentage99.0%
CEO tenure30.1yrs
CEO ownership0.009%
Management average tenure3.2yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

Mar 06
A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking

Dec 29
China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking

Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

Oct 30
Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)

Is China NT Pharma Group (HKG:1011) Using Too Much Debt?

Apr 13
Is China NT Pharma Group (HKG:1011) Using Too Much Debt?

CEO Compensation Analysis

How has David Ng's remuneration changed compared to China NT Pharma Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥28m

Mar 31 2024n/an/a

-CN¥31m

Dec 31 2023CN¥2mCN¥2m

-CN¥33m

Jun 30 2023n/an/a

-CN¥27m

Mar 31 2023n/an/a

-CN¥38m

Dec 31 2022CN¥2mCN¥2m

-CN¥50m

Sep 30 2022n/an/a

-CN¥121m

Jun 30 2022n/an/a

-CN¥175m

Mar 31 2022n/an/a

-CN¥162m

Dec 31 2021CN¥2mCN¥1m

-CN¥150m

Sep 30 2021n/an/a

-CN¥147m

Jun 30 2021n/an/a

-CN¥145m

Mar 31 2021n/an/a

-CN¥167m

Dec 31 2020CN¥2mCN¥2m

-CN¥189m

Sep 30 2020n/an/a

-CN¥271m

Jun 30 2020n/an/a

-CN¥353m

Mar 31 2020n/an/a

-CN¥351m

Dec 31 2019CN¥6mCN¥6m

-CN¥350m

Sep 30 2019n/an/a

-CN¥547m

Jun 30 2019n/an/a

-CN¥744m

Mar 31 2019n/an/a

-CN¥670m

Dec 31 2018CN¥9mCN¥6m

-CN¥596m

Compensation vs Market: David's total compensation ($USD228.99K) is about average for companies of similar size in the Hong Kong market ($USD229.68K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Ng (60 yo)

30.1yrs

Tenure

CN¥1,669,000

Compensation

Mr. Tit Ng, also known as David, has been the Chief Executive Officer and Chairman of China NT Pharma Group Company Limited since 1995. He is a Co-Founder of NT Pharma Group Company Limited. Mr. Ng was app...

Leadership Team

NamePositionTenureCompensationOwnership
Tit Ng
Co-Founder30.1yrsCN¥1.67m0.0095%
HK$ 6.1k
Jing Fang
Chief Financial Officer5.3yrsno datano data
Ching Mei Ng
Executive Director1.1yrsno datano data
Cheung Cheng
Company Secretary1.2yrsno datano data

3.2yrs

Average Tenure

44yo

Average Age

Experienced Management: 1011's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Tit Ng
Co-Founder30.1yrsCN¥1.67m0.0095%
HK$ 6.1k
Ching Mei Ng
Executive Director1.1yrsno datano data
Yu Chin
Non-Executive Director14.9yrsCN¥138.00k0.0095%
HK$ 6.1k
Wei Qian
Non-Executive Director14.9yrsno datano data
Tze Shan Yu
Independent Non-Executive Director7.7yrsCN¥138.00k0.0057%
HK$ 3.7k
Ming Kwan Ng
Independent Non-Executive Director2.1yrsCN¥138.00kno data
Yubiao Zhao
Independent Non-Executive Director5.2yrsCN¥138.00kno data

7.7yrs

Average Tenure

60yo

Average Age

Experienced Board: 1011's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/08 23:23
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

China NT Pharma Group Company Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
P. TingCGS International
Lewis PangCinda International Research Limited
Sze Chuen TamCore Pacific -Yamaichi International (H.K.) Limited